Obesity

Results also showed that older adults, men, and Black adults face an increased risk of advanced stages of CKM syndrome.

Your daily dose of the clinical news you may have missed.

Naim Alkhouri, MD, a transplant hepatologist and a resmetirom investigator, talks here about the life-changing impact the drug will have for all touched by MASH.

Primary care is where early detection and treatment of liver disease should begin and as Dr Alkhouri highlights here, all the right tools are already at hand.

The national study on the true prevalence of metabolic dysfunction-associated liver disease is essential to screening, prevention, and treatment efforts, says AFL CEO Stiehl.

Adults receiving semaglutide for the first time achieved weight loss of 14.3% at 12 months vs 10.6% among those who had previously taken a different antiobesity drug.

Your daily dose of the clinical news you may have missed.

Among persons with COPD whose BMI decreased over a 4-year follow-up, mortality risk rose 70% compared with those whose BMI remained the same, researchers reported.

With the rise in demand for newer antiobesity medications, clinicians may face more questions from patients. Here, a primer on the drawbacks and benefits to keep in mind.

Tirzepatide reduced OSA symptoms and body weight in study participants with severe OSA and obesity, regardless of use of positive airway pressure therapy.